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major cardiovascular disease (CVD) outcomes and total mortality in older men.
Methods and Results: A prospective study of 3099 men aged 60e79 years without a history of car-
diovascular disease followed up for an average 11 years during which there were 528 major CVD
events (fatal coronary heart disease [CHD] and non-fatal MI, stroke and CVD death) and 873 total
deaths. A U shaped relationship was seen between serum sodium concentration and major CVD
events and mortality. Hyponatremia (<136 mEq/L) and low sodiumwithin the normal range (136
e138 mEq/L) showed signiﬁcantly increased risk of major CVD events and total mortality
compared to men within the upper normal range (139e143 mEq/L) after adjustment for a wide
range of confounders and traditional risk factors [adjusted HRs 1.55 (1.13,2.12) and 1.40 (1.14,1.72)
for major CVD events respectively and 1.30 (1.02,1.66) and 1.30 (1.11,1.53) respectively for total
mortality]. Hyponatremia was associated with inﬂammation, NT-proBNP, low muscle mass and
alkaline phosphatase; these factors contributed to the increased total mortality associated with
hyponatremia but did not explain the increased risk of CVD events associated with hyponatremia
or low normal sodium concentration. Hypernatremia (145 mEq/L) was associated with signif-
icantly increased risk of CVD events and mortality due to CVD causes.
Conclusion: Mild hyponatremia even within the normal sodium range and hypernatremia are
both associated with increased total mortality and major CVD events in older men without
CVD which is not explained by known adverse CV risk factors.
ª 2015 The Authors. Published by Elsevier B.V. on behalf of the Italian Society of Diabetology, the
Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the
Department of Clinical Medicine and Surgery, Federico II University. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Hyponatremia, usually deﬁned as serum sodium concen-
tration <136 mEq/L, is one of the most common electro-
lyte abnormalities observed in hospitalised patients [1]f Primary Care and Population
al Free Campus, London NW3
fax: þ44 02074726871.
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ent of Clinical Medicine and Surgery, Fedand in patients with chronic kidney disease (CKD), coro-
nary heart disease (CHD) and heart failure (HF) [2e3].
Several clinical and epidemiological studies have shown
hyponatremia to be associated with increased total mor-
tality in these patients [4e6]. In recent years, attention has
turned to the possibility that mild hyponatremia, may be
associated with adverse outcomes in the general popula-
tion [7]. Studies on hyponatremia and mortality in com-
munity based populations are limited, but in the three
population studies that have examined the relationship
between hyponatremia and mortality in community basediety of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian
erico II University. This is an open access article under the CC BY license (http://
Serum sodium and cardiovascular disease 13subjects, there is evidence that hyponatremia is associated
with increased mortality [8e10] and that even a level of
sodium concentration in the lower normal range (serum
sodium 135e137 mEq/L), a level usually considered
benign, is associated with increased mortality [9]. There is
a paucity of data on electrolyte disturbance and risk of
incident cardiovascular disease in the general population,
but two studies have reported that low serum sodium,
even within the normal range, is associated with increased
stroke risk [11e12], and possibly also to myocardial
infarction [9]. Electrolyte disorders are common in the
elderly [13] but less is known about the relationship be-
tween electrolyte disturbances and incident major CVD
events and mortality in the general older population
without established CVD. We have examined the associa-
tion between serum sodium as well as serum potassium
and risk of CHD, stroke, CVD mortality and total mortality
in a population of older men aged 60e79 years with no
history of CVD (CHD, HF or stroke).
Methods
The British Regional Heart Study is a prospective study of
cardiovascular disease involving 7735 men aged 40e59
years drawn from one general practice in each of 24 British
towns,whowere screened between 1978 and 1980 [14]. The
population studied was socio-economically representative
of British men and consisted almost entirely of white Euro-
peans (>99%). In 1998e2000, all surviving men, now aged
60e79 years, were invited for a 20th year follow-up exami-
nation, on which the analyses presented here are based.
Ethical approval was obtained from all relevant local
research ethics committees. All men completed a mailed
questionnaire providing information on their lifestyle and
medical history, had a physical examination and provided a
fasting blood sample collected using the SarstedtMonovette
system. The sampleswere frozen and stored at20 Con the
day of collection and transferred in batches for storage at
70 C until analysis, carried out after no more than one
freezeethaw cycle. The men were asked whether a doctor
had ever told them that they had angina or myocardial
infarction (MI), HF or stroke and to bring theirmedication to
the examination session. 4252 men (77% of survivors)
attended for the 1998e2000 examination and blood serum
samples were available from 4088 men; 4034 men had
measurements of sodium. Of these men, 935 menwith pre-
existing doctor diagnosed CHD (angina or MI), stroke or
heart failure were excluded, leaving 3099 men for analyses.
Cardiovascular risk factor measurements at 1998e2000
Details of measurement and classiﬁcation methods for
smoking status, physical activity, body mass index, social
class, alcohol intake, blood pressure, blood lipids, alkaline
phosphatase and forced expiratory volume in 1 s (FEV1) in
this cohort have been described [15e17]. Mid arm muscle
circumference (MAMC) calculated as mid upper arm
circumference (MUAC) e 0.3142*(triceps skinfold thick-
ness) was considered an indicator of muscle mass [16,18].Prevalent diabetes included men with a diagnosis of dia-
betes or men with fasting blood glucose 7 mmol/l. Pre-
dicted glomerular ﬁltration rate (eGFR), estimated from
serum creatinine using the equation developed by Levey
et al. [19] was used as a measure of renal function. C-
reactive protein (CRP) was assayed by ultra sensitive
nephelometry (Dade Behring, Milton Keynes, UK) [20]. N-
terminal pro-brain natriuretic peptide (NT-proBNP) was
determined using the Elecsys 2010 electro-
chemiluminescence method (Roche Diagnostics, Burgess
Hill, UK) [21].
Serum sodium
Sodium was measured by an ion selective electrode. A
membrane composed of crown ether with a neutral PVC
carrier forms a selective membrane for sodium ions,
creating an electrical potential as sodium ions traverse the
membrane [22]. The electrical potential can be compared
to a reference electrode to determine the sodium ion
concentration. The between batch imprecision was <2%.
Follow-up
All men have been followed up from initial examination
(1978e1980) for cardiovascular morbidity [23] and follow-
up has been achieved for 99% of the cohort. In the present
analyses, total mortality and morbidity events are based on
follow-up from re-screening in 1998e2000 at mean age
60e79 years to June 2010, a mean follow-up period of 11
years (range 10e12). Information on death was collected
through the established “tagging” procedures provided by
the National Health Service registers. Fatal stroke episodes
were those coded on the death certiﬁcate to International
Classiﬁcation of Diseases (ICD-9th Revision) 430e438.
Non-fatal stroke events were those which produced a
neurological deﬁcit that was present for more than 24 h.
Fatal CHD events were deﬁned as death with CHD (ICD 9th
revision, codes 410e414) as the underlying code. A non-
fatal MI was diagnosed according to World Health Orga-
nisation criteria [24]. Cardiovascular deaths included all
those with ICD-9 codes 390e459. Evidence of non-fatal MI
and HF was obtained by ad hoc reports from general
practitioners supplemented by biennial reviews of the
patients’ practice records (including hospital and clinic
correspondence) through to the end of the study period.
Outcomes assessed in the current analyses were major
CHD (deﬁned as fatal or non-fatal MI) major stroke events
(fatal or non-fatal), CVD death and all major CVD events
(major CHD events, stroke events or CVD death).
Statistical methods
Cox’s proportional hazards model was used to assess the
multivariate-adjusted hazards ratio (relative risk) by levels
of serum sodium. Tests for quadratic trends in Fig. 1 were
assessed by assigning quantitative values (1e11) for the 11
groups and ﬁtting sodium as a continuous variable rather
than as categorical variables and including a quadratic
term. In multivariate analyses, smoking (never, long term
ex-smokers (>15 years), recent ex-smokers (<15 years)
and current smokers), social class (manual vs non manual),
Figure 1 Serum sodium concentrations and incident cardiovascular
rates/1000 person-years and total mortality rates/1000 person years.
Number of men: Sodium levels <136 (n Z 207), 136 (n Z 134), 137
(nZ 234), 138 (nZ 330), 139 (nZ 463), 140 (nZ 494), 141 (nZ 491),
142 (n Z 337), 143 (n Z 244), 144 (n Z 109), 145 (n Z 56).
14 S.G. Wannamethee et al.physical activity (4 groups), alcohol intake (5 groups),
diabetes (yes/no), BMI (<25, 25e27.5, 27.5e29.9 and
30þ kg/m [2]), eGFR (<60, 60e69, 70 ml/min per
1.73 m2) and muscle mass (quartiles) were ﬁtted as cate-
gorical variables; FEV1, HDL-C, CRP, systolic blood pres-
sure, alkaline phosphatase, and NT-proBNP were ﬁtted as
continuous variables.Results
The mean serum sodium level in the 3099 men without
CHD, stroke or HF was 139.7 mEq/L, SD (2.67) (range
125e150 mEq/L). Hyponatremia (<136 mEqu/L) was pre-
sent in 6.7% of the men and hypernatremia (145 mEq/L)
in 1.8% of men; only 15 men (0.5%) had levels above
145mEq/L. During the mean follow-up time of eleven years
there were 269 CHD events, 209 stroke events and 293
CVD deaths, a total of 528 major incident CVD events
(stroke, CHD, CVD deaths) in these men. Figure 1 shows
the rates/1000 person years for overall CVD events and
total mortality by levels of serum sodium concentration. A
signiﬁcant U-shaped relationship was seen with overallCVD events and total mortality with risk increasing below
levels of 139 mEq/L and above 143 mEq/L (both p < 0.0001
for quadratic trend). On the basis of these ﬁndings we
grouped the men into ﬁve categories: <136 (hypona-
tremia), 136e138 (low normal), 139e143, 144 and  145
(hypernatremia) mEq/L.
Baseline characteristics by sodium
Table 1 shows the baseline characteristics by the ﬁve so-
dium groups. Hyponatremia was associated with older age
and increased prevalence of smoking, heavier alcohol
intake, diabetes and diuretic use. BMI and muscle mass
tended to increase with increasing sodium levels. Hypo-
natremia was associated with the highest levels of CRP, NT-
proBNP (marker of neurohormonal activation), GGT, alka-
line phosphatase and eGFR and the lowest levels of FEV1.
Overall, men with hypernatremia showed similar charac-
teristics to those with normal sodium levels.
Sodium and CVD risk
Men with sodium levels below 139 mEq/L and men with
hypernatremia showed signiﬁcantly higher risk of major
CVD events than menwith sodium levels between 139 and
143 mEq/L, even after adjustment for potential con-
founders, diabetes, blood pressure, blood lipids, lung
function and eGFR (Table 2; model 1) and muscle mass
(model 2). Further adjustment for CRP, alkaline phospha-
tase and NT-proBNP (model 3) made minor differences to
the ﬁndings. When examined separately for CHD and
stroke the increased risk associated with low sodium was
seen for both CHD and stroke events and CVD death
although hyponatremia related more to stroke events than
CHD events. Hypernatremia related particularly strongly to
stroke and CVD deaths. These associations persisted even
after exclusion of men with renal dysfunction (eGFR <60),
diuretic use and current smokers (N Z 569) (Table 2).
Sodium and total mortality
Hyponatremia and low sodium levels were associated with
signiﬁcantly increased mortality (Table 3). The increased
risk of total mortality in men with hyponatremia was to
some extent associated with muscle mass, CRP, alkaline
phosphatase and NT-proBNP (Table 1). Men with hyper-
natremia showed increased risk in mortality compared to
men with normal sodium levels, although the difference
was not signiﬁcant. The increased risk of mortality seen in
those with low normal serum sodium was attenuated but
remained signiﬁcant even after exclusion of men with
renal dysfunction (eGFR <60), diuretic use and current
smokers (Table 3).
Potassium and CVD and total mortality
Only 12 men were classiﬁed as having hypokalaemia
(<3.5 mEq/L) and 107 men were classiﬁed as having
hyperkalaemia (>5.0 mEq/L). In contrast to serum sodium,
Table 1 Baseline characteristics according to sodium levels (mEqu/L) in 3099 men with no diagnosed CHD, stroke or heart failure.
Sodium (mEq/L)
<136 (N Z 207) 136-138 (N Z 698) 139-143 (N Z 2029) 144 (N Z 109) 145 (N Z 56) P overall
difference
Age (yrs) 69.8 (5.53) 68.6 (5.47) 68.0 (5.35) 68.6 (5.47) 68.2 (5.74) <0.0001
% current smokers 18.0 14.9 12.2 10.2 7.3 0.04
% active 13.9 8.6 5.2 12.3 3.9 0.02
% manual 54.6 58.3 51.4 48.6 53.1 0.02
% moderate/heavy drinkers 22.7 19.5 19.3 9.2 12.5 0.03
% diabetes 15.9 16.2 7.8 15.9 8.9 <0.0001
% cancer 3.9 6.5 5.6 1.9 1.8 P Z 0.19
% antihypertensive drugs 30.4 23.2 23.3 19.3 23.2 0.15
% diuretics 10.5 8.1 5.7 4.7 7.6 0.03
% statins 1.9 1.3 2.5 1.8 1.8 0.43
BMI (kg/m2) 25.8 (3.52) 26.8 (3.76) 26.8 (3.46) 27.4 (3.95) 27.1 (3.14) 0.001
Muscle mass (kg) 25.5 (2.51) 26.2 (2.29) 26.6 (2.33) 26.7 (2.13) 28.9 (2.29) <0.0001
SBP (mmHg) 151.3 (23.8) 149.0 (22.6) 150.4 (24.1) 148.5 (24.3) 156.6 (25.1) 0.14
Cholesterol (mmol/l) 5.89 (1.14) 6.15 (1.06) 6.07 (1.05) 6.13 (1.03) 5.90 (1.26) 0.02
HDL-C (mmol/l) 1.38 (0.35) 1.35 (0.37) 1.33 (0.34) 1.32 (0.29) 1.27 (0.31) 0.11
Glucose*(mmol/l) 6.23 (5.26e6.25) 6.05 (5.31e6.29) 5.70 (5.24e6.02) 5.64 (5.20e5.89) 5.75 (5.17e5.79) <0.0001
FEV1 (L) 2.40 (0.73) 2.60 (0.66) 2.67 (0.65) 2.54 (0.56) 2.68 (0.69) <0.0001
CRP*(mg/L) 2.24 (0.88e5.55) 1.73 (0.78e3.59) 1.57 (0.78e3.09) 1.72 (0.89e3.75) 1.36 (0.70e2.85) <0.0001
eGFR(ml/min per 1.73 m2) 76.1 (11.6) 73.4 (12.3) 72.7 (12.2) 69.1 (11.0) 73.5 (21.8) <0.0001
NT-proBNP 109.9 (52e205) 81.5 (41e154) 80.6 (40e147) 90.0 (42e182) 93.7 (50e202) 0.004
ALP 86.5 (71e108) 79.8 (66e94) 80.6 (68e94) 85.6 (67e99) 83.1 (69e95) 0.006
GGT 33.1 (20e44) 28.8 (19e38) 27.7 (19e38) 27.1 (19e38) 27.7 (18e32) 0.0007
Blood urea 5.52 (1.52) 5.88 (1.73) 5.98 (1.51) 5.89 (1.26) 6.17 (1.42) 0.001
Mean and SD; * geometric mean and interquartile range.
Serum sodium and cardiovascular disease 15no consistent associationwas seen between potassium and
overall CVD events (Fig. 2). A shallow but non-signiﬁcant U
shaped association was seen between potassium and total
mortality with mortality highest in the very small groups
of men with hypokalaemia and men with levels >5.3 mEq/
L (n Z 27) (Fig. 2).Discussion
In this study of older men without established CVD or HF,
there was a U-shaped association between serum sodium
and CVD events and mortality, with the lowest levels of
risk in the 139e143 mEq/L group. Hyponatremia
(<136 mEq/L) was present in about 6.7% of the population,
a similar proportion to that observed in other healthy
older populations [12]. Although hyponatremia is usually
deﬁned as levels <136 mEq/L [1], a more conservative
deﬁnition of hyponatremia (sodium levels <138 mEq/L)
was suggested by Kumar and Berl [25]. The signiﬁcantly
increased risk of CVD and mortality seen at circulating
sodium levels between 136 and 138 mEq/L in the present
study supports this more conservative deﬁnition and
suggests that in older adults even levels between 136 and
138 mEq/L levels usually considered to be within the
normal range (present in nearly a quarter of the men), may
be a marker of mortality and CVD risk. Hypernatremia in
this population was uncommon but was associated with
signiﬁcantly higher risk of both CVD events and increased
CVD mortality. By contrast, serum potassium showed no
signiﬁcant association with total mortality or CVD events,
which is consistent with a previous report [10]. Our studyconﬁrms other population studies that have shown mild
hyponatremia to be associated with increased mortality
[9] and extends the ﬁndings to cardiovascular events. We
were able to examine a wide range of potential con-
founders and mediators in assessing the sodium CVD/
mortality relationship including muscle mass, alkaline
phosphatase (a biochemical marker of bone turnover) [17]
and NT-proBNP (marker of neurohormonal activation).Low circulating sodium concentration and total
mortality
In the majority of studies, predeﬁned cut-off points have
been used and comparisons are made between hypona-
tremic subjects and normonatremic subjects. We have
shown that mortality decreases with increasing levels up
to levels of 139 and levels out thereafter, rising again at
levels above 144 (hypernatremia) which is similar to other
studies conducted in hospital and CKD patients [6].
Hyponatraemia has several mechanisms, which could
contribute to the relationship observed. Clinical studies
have shown that neurohormonal activity (NT-proBNP),
inﬂammation, diabetes and muscle mass are determinants
of hyponatremia [3]. Recent studies suggest that hypona-
tremia could also affect other organs including lung and
bone abnormalities [26,27]. We have observed that hypo-
natremia is associated with several adverse risk factors
including smoking, low muscle mass, low lung function,
inﬂammation, increased levels of NT-proBNP, diabetes and
increased levels of alkaline phosphatase, factors shown be
associated with increased CVD and or mortality in this
Table 2 Incidence rates/1000 person years and adjusted hazards ratios (95%CI) for major cardiovascular events by serum sodium levels (mEqu/L)
in 3099 men without CHD, stroke or heart failure.
Serum sodium (mEq/L)
<136 (NZ 207) 136-138 (NZ 698) 139-143 (NZ 2029) 144 (NZ 109) 145 (N Z 56)
All CVD events (n Z 528)
Rate/1000 per-yrs 27.7 (49) 22.1 (140) 15.3 (303) 19.3 (20) 32.7 (16)
Age-adjusted 1.50 (1.11,2.07) 1.42 (1.16,1.73) 1.00 1.20 (0.76,1.88) 2.20 (1.33,3.63)
Model 1 1.55 (1.13,2.12) 1.40 (1.14,1.72) 1.00 1.24 (0.78,2.00) 2.24 (1.33,3.65)
Model 2 1.52 (1.10,2.09) 1.38 (1.12,1.69) 1.00 1.23 (0.77,2.00) 2.16 (1.30,3.50)
Model 3 1.48 (1.08,2.04) 1.43 (1.16,1.76) 1.00 1.20 (0.75,1.91) 2.07 (1.23,3.42)
(with exclusiona) 1.46 (1.01,2.10) 1.31 (1.02,1.67) 1.00 1.01 (0.56,0.82) 2.38 (1.31,4.32)
CHD events (n Z 269)
Rate/1000 per-yrs (n) 10.7 (20) 11.2 (73) 7.8 (158) 10.4 (11) 13.2 (7)
Age-adjusted 1.17 (0.73,1.86) 1.40 (1.06,1.85) 1.00 1.28 (0.70,2.36) 1.71 (0.80,3.64)
Model 1 1.19 (0.73,1.94) 1.39 (1.05,1.85) 1.00 1.36 (0.74,2.52) 1.71 (0.80,3.66)
Model 2 1.14 (0.70,1.86) 1.34 (1.01,1.79) 1.00 1.40 (0.76,2.59) 1.69 (0.79,3.62)
Model 3 1.18 (0.72,1.93) 1.45 (1.09,1.94) 1.00 1.37 (0.74,2.54) 1.63 (0.76,3.50)
(with exclusiona) 1.20 (0.69,2.10) 1.46 (1.04,2.04) 1.00 1.03 (0.45,2.35) 1.68 (0.67,4.21)
Stroke events (nZ 209)
Rate/1000 per-yrs 15.6 (28) 8.1 (52) 5.7 (116) 5.7 (6) 14.2 (7)
Age-adjusted 2.29 (1.51,3.48) 1.38 (1.00,1.92) 1.00 0.94 (0.42,2.15) 2.54 (1.19,5.46)
Model 1 2.30 (1.49,3.55) 1.43 (1.02,2.00) 1.00 0.86 (0.35,2.11) 2.60 (1.21,5.62)
Model 2 2.28 (1.48,3.53) 1.43 (1.02,2.00) 1.00 0.86 (0.35,2.11) 2.57 (1.19,5.54)
Model 3 2.12 (1.37,3.28) 1.42 (1.02,2.50) 1.00 0.83 (0.34,2.04) 2.49 (1.15,5.39)
(with exclusiona) 2.02 (1.23,3.32) 1.14 (0.76,1.71) 1.00 0.80 (0.29,2.18) 2.58 (1.04,6.45)
CVD deaths (n Z 293)
Rate/1000 per-yrs 15.3 (29) 12.8 (85) 7.6 (156) 13.0 (14) 16.7 (9)
Age-adjusted 1.55 (1.04,2.30) 1.62 (1.24,2.11) 1.00 1.63 (0.94,2.81) 2.25 (1.15,4.41)
Model 1 1.60 (1.05,2.43) 1.58 (1.20,2.08) 1.00 1.77 (1.00,3.14) 2.38 (1.21,4.69)
Model 2 1.53 (1.01,2.34) 1.53 (1.16,2.01) 1.00 1.81 (1.02,3.26) 2.32 (1.17,4.57)
Model 3 1.61 (1.05,2.46) 1.64 (1.24,2.16) 1.00 1.73 (0.98,3.08) 2.25 (1.14,4.47)
(with exclusiona) 1.68 (1.03,2.73) 1.58 (1.12,2.22) 1.00 1.19 (0.52,2.73) 2.57 (1.09,6.03)
Model 1 Z adjusted for age, cigarette smoking, alcohol intake, physical activity, social class, BMI use of antihypertensive drugs, diabetes, lung
function, systolic blood pressure and eGFR.
Model 2 adjusted for Model 1 þ muscle mass.
Model 3 Adjusted for Model 1 þ CRP þ alkaline phosphatase þ NT-proBNP.
a Exclude men with diuretic use, renal dysfunction (eGFR<60) and current smokers.
16 S.G. Wannamethee et al.study [16,17,20,21]. These factors contributed to the
increased total mortality risk in those with hyponatremia.
However, they did not explain the increased total mortality
risk seen at low sodium levels within the normal range.
Low circulating sodium concentration and CVD risk
Few studies have examined the association between
serum sodium and CVD. A previous report has suggested
hyponatremia and low sodium (135e137 mEq/L), referred
to as subtle hyponatremia, to be associated with increased
risk of MI but the study was based on very small numbers
with sodium levels (<138 mEq/L) (n Z 76) [9]. Our study
conﬁrms a signiﬁcant association between low sodium
(but not hyponatremia) and major CHD (non-fatal MI and
CHD deaths) which was not explained by known risk
factors for CHD. The lack of association with CHD events
with hyponatremia may be due to competing stroke
events as these men showed exceptionally high risk of
stroke. Our earlier report, conducted in middle-aged when
the men were aged 40e59 years showed an association
between low sodium and hypernatremia and increased
risk of stroke [11]. This ﬁnding was conﬁrmed in this
population of men now aged 60e79 years and is consistentwith ﬁndings from another cohort of older men showing
sodium levels <140 mEq/L to increase stroke mortality risk
[12]. The mechanisms underlying the relation between
serum sodium and stroke are not clear, but it seems likely
that different mechanisms are operating at the lower and
higher ends of the serum sodium distribution. It is well
recognized that acute changes in either direction cause
cerebral disorders. Hyponatremia is known to affect the
central nervous system and cause cerebral edema [28].
However, the increased risk of stroke was seen evenwithin
normal ranges, which was not explained by established
risk factors for stroke.
The U shaped association between serum sodium and
CVD is similar to the U-shaped association seen between
dietary sodium intake as measured by urinary sodium
excretion and CVD [29]. Although dietary sodium intake is
shown to have a small effect on increasing circulating
serum sodium levels [30], low circulating serum sodium
under normal circumstances however, does not reﬂect low
dietary sodium intake. The U-shaped association seen
between serum sodium and CVD is thus unlikely to reﬂect
dietary sodium intake. Speculatively, it is possible that the
renin-angiotensin-aldosterone system (RAAS) might play
an important role in the association between low sodium
Table 3 Mortality rates/1000 person years (number of deaths) and adjusted hazards ratios (95%CI) for total mortality in men without CHD,
stroke or heart failure.
Serum sodium (mEq/L)
<136 (N Z 207) 136e138 (N Z 698) 139e143 (NZ 2029) 144 (NZ 109) 145 (N Z 56)
Total mortality (n Z 873)
Rate/1000 per-yrs (n) 43.9 (83) 34.8 (230) 24.6 (508) 30.7 (33) 35.4 (14)
Age-adjusted 1.47 (1.16,1.85) 1.39 (1.19,1.62) 1.00 1.19 (0.84,1.69) 1.48 (0.94,2.34)
Model 1 1.30 (1.02,1.66) 1.30 (1.11,1.53) 1.00 1.25 (0.87,1.78) 1.54 (0.97,2.44)
Model 2 1.27 (0.99,1.62) 1.27 (1.08,1.49) 1.00 1.27 (0.88,1.81) 1.52 (0.96,2.41)
Model 3 1.24 (0.97,1.59) 1.33 (1.13,1.56) 1.00 1.20 (0.83,1.73) 1.46 (0.92,2.32)
(With exclusiona) 1.23 (0.94,1.63) 1.22 (1.01,1.47) 1.00 1.20 (0.83,1.73) 1.53 (0.85,2.75)
Model 1 Z adjusted for age, cigarette smoking, alcohol intake, physical activity, social class, BMI, use of antihypertensive drugs, diabetes, lung
function, systolic blood pressure and eGFR.
Model 2 Z Model 1 þ muscle mass.
Model 3 Z Model 1 þ muscle mass þ CRP þ alkaline phosphatase þ NT-proBNP.
a Exclude men with diuretic use, renal dysfunction (eGFR<60) and current smokers.
Serum sodium and cardiovascular disease 17and CVD events. As a component of the RAAS system,
aldosterone is an important mineralocortoid hormone
involved in the regulation of ﬂuid and electrolyte home-
ostatsis and has been associated with increased risk of CVD
mortality [31]. Low sodium may have direct inﬂuence onFigure 2 Serum potassium concentrations and incident cardiovascular
rates/1000 person-years and total mortality rates/1000 person years.
Number of men <3.5 (n Z 12), 3.5e3.8 (n Z 118), 3.9e4.0 (n Z 341),
4.1e4.2 (n Z 535), 4.3e4.4 (n Z 664), 4.5e4.6 (n Z 652), 4.7e4.8
(n Z 209), 4.9e5.0 (n Z 444), 5.1e5.2 (n Z 68), 5.3 (n Z 39).CVD events by decreasing bone mineral density [26] which
has been linked to increased risk of CVD [17]. Alternatively
low normal serum sodium may represent a risk marker for
poor health, rather than a risk factor for CVD or mortality.
However, low normal serum sodium was related to CVD
risk even in the absence of diuretic use, renal dysfunction
and smoking.
Hypernatremia
Hypernatremia is a common electrolyte disturbance in
hospitalized patients and is well recognized to be associ-
ated with increased mortality [32]. Hypernatremia
(145 mEq/L) was uncommon in this community dwelling
older population without CVD or HF but was associated
with signiﬁcantly increased mortality largely due to CVD
causes. The association seen more speciﬁcally for stroke
which was not explained by diuretic use or renal
dysfunction (as measured by the eGFR), common causes of
hypernatremia, is consistent with the ﬁndings that
hypernatremia is common in patients presenting with
stroke at time of hospitalization [32].
Strengths and limitations
Strengths and limitations of the study require consider-
ation. This study is based on a cohort of older (60e79 year
old) men who constitute a high risk group in whom
electrolyte disturbances are common and in whom tradi-
tional risk factors are less predictive. Our results need
conﬁrmation both in similar older study populations and
also in middle-aged populations and in particular women.
The study population is socially representative of the UK,
and follow-up rates in the British Regional Heart Study are
exceptionally high. Ascertainment of CHD death and MI is
based on standard methods and both CHD mortality and
MI incidence rates correspond closely with national data.
We were able to take into account a wide range of CV risk
factors including markers of inﬂammation and cardiac
markers. However, blood measurements were based on
one measurement. Comparisons of sodium levels
18 S.G. Wannamethee et al.measured 20 years earlier in these men showed that 50%
of those with low normal sodium levels (136e138 mEq/L)
at baseline in 1978e1980 continued to have low normal or
low serum sodium 20 years later while 50% had reverted
to normal value. Overall tracking of sodium concentrations
over the 20 year period was modest (r Z 0.19) but highly
statistically signiﬁcant. However the fact that one sodium
measure revealed an association with CVD risk and mor-
tality suggests that the true association may be even
stronger. Moreover, plasma aldosterone and renin,
important determinants of electrolyte disorders were not
measured in the study.Conclusion and implications
Hyponatremia and hypernatremia are both associated
with increased risk of CVD incidence and mortality. Low
sodium within the normal range is associated with
signiﬁcantly increased CVD events and total mortality in
older menwithout major CVD or HF even in the absence of
diuretic use and renal dysfunction. The data lends further
evidence to the suggestion that the presence of mild
hyponatremia is not benign. The ﬁndings may have
important implications for the monitoring of sodium levels
in clinical practice in older adults. The presence of mild
hyponatremia in the absence of known causes such as
renal dysfunction and diuretics may warrant further
investigation in these men to assess CVD risk factors or
possible underlying ill-health such as chronic inﬂamma-
tion. Further large studies are required to conﬁrm and
elucidate the nature of the association between low
normal sodium and risk of incident CVD.Funding
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